These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

213 related articles for article (PubMed ID: 32556315)

  • 1. Revision of EUCAST breakpoints: consequences for susceptibility of contemporary Danish mould isolates to isavuconazole and comparators.
    Jørgensen KM; Guinea J; Meletiadis J; Hare RK; Arendrup MC
    J Antimicrob Chemother; 2020 Sep; 75(9):2573-2581. PubMed ID: 32556315
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Evaluation of the in vitro activity of isavuconazole and comparator voriconazole against 2635 contemporary clinical Candida and Aspergillus isolates.
    Astvad KMT; Hare RK; Arendrup MC
    Clin Microbiol Infect; 2017 Nov; 23(11):882-887. PubMed ID: 28373148
    [TBL] [Abstract][Full Text] [Related]  

  • 3. EUCAST Susceptibility Testing of Isavuconazole: MIC Data for Contemporary Clinical Mold and Yeast Isolates.
    Jørgensen KM; Astvad KMT; Hare RK; Arendrup MC
    Antimicrob Agents Chemother; 2019 Jun; 63(6):. PubMed ID: 30910898
    [TBL] [Abstract][Full Text] [Related]  

  • 4. How to interpret MICs of antifungal compounds according to the revised clinical breakpoints v. 10.0 European committee on antimicrobial susceptibility testing (EUCAST).
    Arendrup MC; Friberg N; Mares M; Kahlmeter G; Meletiadis J; Guinea J;
    Clin Microbiol Infect; 2020 Nov; 26(11):1464-1472. PubMed ID: 32562861
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Isavuconazole susceptibility of clinical Aspergillus fumigatus isolates and feasibility of isavuconazole dose escalation to treat isolates with elevated MICs.
    Buil JB; Brüggemann RJM; Wasmann RE; Zoll J; Meis JF; Melchers WJG; Mouton JW; Verweij PE
    J Antimicrob Chemother; 2018 Jan; 73(1):134-142. PubMed ID: 29048485
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Gradient diffusion strips for detecting azole resistance in Aspergillus fumigatus sensu lato.
    Serrano-Lobo J; Gómez A; Reigadas E; Muñoz P; Escribano P; Guinea J;
    Mycoses; 2023 Mar; 66(3):196-201. PubMed ID: 36305878
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Nationwide surveillance of azole-resistant Aspergillus fumigatus environmental isolates in Greece: detection of pan-azole resistance associated with the TR46/Y121F/T289A cyp51A mutation.
    Siopi M; Rivero-Menendez O; Gkotsis G; Panara A; Thomaidis NS; Alastruey-Izquierdo A; Pournaras S; Meletiadis J
    J Antimicrob Chemother; 2020 Nov; 75(11):3181-3188. PubMed ID: 32814940
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Comparison of the MICs Obtained by Gradient Concentration Strip and EUCAST Methods for Four Azole Drugs and Amphotericin B against Azole-Susceptible and -Resistant
    Dellière S; Verdurme L; Bigot J; Dannaoui E; Senghor Y; Botterel F; Fekkar A; Bougnoux ME; Hennequin C; Guitard J
    Antimicrob Agents Chemother; 2020 Feb; 64(3):. PubMed ID: 31844011
    [TBL] [Abstract][Full Text] [Related]  

  • 9. In vitro activity of the novel antifungal compound F901318 against difficult-to-treat Aspergillus isolates.
    Buil JB; Rijs AJMM; Meis JF; Birch M; Law D; Melchers WJG; Verweij PE
    J Antimicrob Chemother; 2017 Sep; 72(9):2548-2552. PubMed ID: 28605488
    [TBL] [Abstract][Full Text] [Related]  

  • 10. In vitro susceptibility of Aspergillus fumigatus to isavuconazole: correlation with itraconazole, voriconazole, and posaconazole.
    Gregson L; Goodwin J; Johnson A; McEntee L; Moore CB; Richardson M; Hope WW; Howard SJ
    Antimicrob Agents Chemother; 2013 Nov; 57(11):5778-80. PubMed ID: 24041890
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Isavuconazole: A new broad-spectrum azole. Part 1: In vitro activity.
    Denis J; Ledoux MP; Nivoix Y; Herbrecht R
    J Mycol Med; 2018 Mar; 28(1):8-14. PubMed ID: 29534853
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Azole and Amphotericin B MIC Values against
    Serrano-Lobo J; Gómez A; Sánchez-Yebra W; Fajardo M; Lorenzo B; Sánchez-Reus F; Vidal I; Fernández-Torres M; Sánchez-Romero I; Ruiz de Alegría-Puig C; Del Pozo JL; Muñoz P; Escribano P; Guinea J
    Antimicrob Agents Chemother; 2020 Dec; 65(1):. PubMed ID: 33020164
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Molecular Identification, Antifungal Susceptibility Testing, and Mechanisms of Azole Resistance in
    Rivero-Menendez O; Soto-Debran JC; Medina N; Lucio J; Mellado E; Alastruey-Izquierdo A
    Antimicrob Agents Chemother; 2019 Sep; 63(9):. PubMed ID: 31285229
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Isavuconazole nonwildtype Aspergillus fumigatus isolates from a global surveillance study display alterations in multiple genes involved in the ergosterol biosynthesis pathway not previously associated with resistance to other azoles.
    Castanheira M; Collingsworth TD; Davis AP; Deshpande LM; Pfaller MA
    Mycoses; 2021 Oct; 64(10):1279-1290. PubMed ID: 33705591
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Azole, polyene and echinocandin MIC distributions for wild-type, TR34/L98H and TR46/Y121F/T289A Aspergillus fumigatus isolates in the Netherlands.
    van Ingen J; van der Lee HA; Rijs TA; Zoll J; Leenstra T; Melchers WJ; Verweij PE
    J Antimicrob Chemother; 2015 Jan; 70(1):178-81. PubMed ID: 25301884
    [TBL] [Abstract][Full Text] [Related]  

  • 16. In vitro activity of isavuconazole versus opportunistic filamentous fungal pathogens from the SENTRY Antifungal Surveillance Program, 2017-2018.
    Messer SA; Carvalhaes CG; Castanheira M; Pfaller MA
    Diagn Microbiol Infect Dis; 2020 May; 97(1):115007. PubMed ID: 32081523
    [TBL] [Abstract][Full Text] [Related]  

  • 17.
    Pfaller MA; Rhomberg PR; Wiederhold NP; Gibas C; Sanders C; Fan H; Mele J; Kovanda LL; Castanheira M
    Antimicrob Agents Chemother; 2018 Oct; 62(10):. PubMed ID: 30061288
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Trends in the activity of mold-active azole agents against
    Pfaller MA; Carvalhaes CG; Rhomberg PR; Desphande LM; Castanheira M
    J Clin Microbiol; 2024 Feb; 62(2):e0114123. PubMed ID: 38193696
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Determination of isavuconazole susceptibility of Aspergillus and Candida species by the EUCAST method.
    Howard SJ; Lass-Flörl C; Cuenca-Estrella M; Gomez-Lopez A; Arendrup MC
    Antimicrob Agents Chemother; 2013 Nov; 57(11):5426-31. PubMed ID: 23959309
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Candida and candidaemia. Susceptibility and epidemiology.
    Arendrup MC
    Dan Med J; 2013 Nov; 60(11):B4698. PubMed ID: 24192246
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.